Anthropic Acquires Coefficient Bio In $400 Million Deal
Anthropic has acquired Coefficient Bio, a biotech AI startup, in a $400 million deal to strengthen its ambitions in biotech research and drug discovery. The acquisition enhances Anthropic's talent resources and knowledge base, positioning it as a major force in AI-based drug discovery.
Anthropic has acquired Coefficient Bio, a New York-based biotech AI startup, in a stock deal worth $400 million. Coefficient Bio developed AI systems for biotech tasks such as drug R&D planning and identifying new drug candidates. The acquisition gives Anthropic a stronger foothold in healthcare and life sciences. Coefficient Bio's founders, Samuel Stanton and Nathan C. Frey, have backgrounds in machine learning and biological base models. The Coefficient Bio team is expected to join Anthropic's healthcare and life sciences division. The acquisition highlights a trend of Genentech talent moving into AI-native biotech companies.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.